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Abstract
Background: Weight loss and under-nutrition are relatively common in older people, and are associated with poor
outcomes including increased rates of hospital admissions and death. In a pilot study of 49 undernourished older,
community dwelling people we found that daily treatment for one year with a combination of testosterone tablets and
a nutritional supplement produced a significant reduction in hospitalizations. We propose a larger, multicentre study to
explore and hopefully confirm this exciting, potentially important finding (NHMRC project grant number 627178).
Methods/Design: One year randomized control trial where subjects are allocated to either oral testosterone
undecanoate and high calorie oral nutritional supplement or placebo medication and low calorie oral nutritional
supplementation. 200 older community-dwelling, undernourished people [Mini Nutritional Assessment score <24
and either: a) low body weight (body mass index, in kg/m
2: <22) or b) recent weight loss (>7.5% over 3 months)].
Hospital admissions, quality-adjusted life years, functional status, nutritional health, muscle strength, body
composition and other variables will be assessed.
Discussion: The pilot study showed that combined treatment with an oral testosterone and a supplement drink
was well tolerated and safe, and reduced the number of people hospitalised and duration of hospital admissions
in undernourished, community dwelling older people. This is an exciting finding, as it identifies a treatment which
may be of substantial benefit to many older people in our community. We now propose to conduct a multi-centre
study to test these findings in a substantially larger subject group, and to determine the cost effectiveness of this
treatment.
Trial registration: Australian Clinical Trial Registry: ACTRN 12610000356066
Background
Ageing is associated with a physiological reduction of
appetite and food intake [1,2]. Mean body weight
decreases after about 60 years [3,4], largely due to a loss
of muscle mass [5]. This age-associated loss of muscle
mass and strength is called sarcopenia [6,7], which is
present in up to 6-15% of older people [7]. Sarcopenia is
associated with an increased risk of falls, disability and
mortality [8-11]. The combination of muscle loss and
reduced food intake predisposes older people to develop
under-nutrition, which occurs in up to 10-15% of com-
munity-dwelling older people and many more in nursing
homes [2,9]. Low body weight [10] and weight loss, par-
ticularly if involuntary, are major markers of harmful
under-nutrition in older people [9,11].
In frail, malnourished, elderly people in nursing homes
or hospital, daily oral nutritional (often high protein) sup-
plementation has been shown to result in increased
energy intake and body weight, reduced post-operative
complications and length of hospital stay, and even
reduced mortality [12,13]. The benefits of nutritional
supplements have not been clearly established in frail,
community-dwelling older people [14]. Circulating
androgen concentrations decline in both men [15] and
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evidence that this contributes to the development of
sarcopenia and the declining functional status that occurs
with ageing [17,18]. Testosterone administration to older
men has been shown to increase muscle mass and
decrease fat mass [19-21]. In addition, it has been shown
to increase muscle strength, albeit modestly and variably,
more with high doses and in men with low testosterone
levels [20,22,23]. In postmenopausal women testosterone
treatment increases lean body mass, energy and libido
[24,25] and possibly muscle strength [24]. We are una-
ware of evidence that testosterone improves clinically
relevant outcomes, such as physical performance or cog-
nitive function, in older women [24,26]. There have been
a few reports of functional benefits of testosterone
administration to older men; testosterone in high doses
has been reported to improve standing ability after knee
replacement surgery [27], improve timed walking[20] and
increase the Function Independence Measure and grip
strength [21]. Whilst androgen replacement therapy is
advocated for men with low testosterone concentrations
and symptoms of marked androgen deficiency, there is
no consensus for its use in elderly men with less severe
ageing-related declines in androgen concentrations, or in
elderly women.
Hospitalisation is common in older people and imposes
major burdens on the individual and community. Frail
older people and those at nutritional risk are at increased
risk of hospitalisation [28,29]. Our research group have
previously reported that 43.2% of community dwelling
recipients of domiciliary care services in Adelaide were
under-nourished (38.4% of subjects at risk of malnutri-
tion, 4.8% malnourished). 45% of these undernourished
people were hospitalised in the subsequent year, a signifi-
cantly higher rate than in well-nourished controls, with a
3-fold higher rate of hospitalization for more than one
month [29]. As well as indicating the presence of an ill-
ness or illnesses sufficiently serious to require hospital
admission, hospitalisation in older people is associated
frequently with complications such as delirium, declining
muscle strength and respiratory function, and is often
followed by functional decline [30]. In older people there
is a strong relationship between hospitalisation and the
later development of disability, including disability severe
enough to require moving to residential aged care
[28,31]. Disability in older people is strongly associated
with increased morbidity and mortality [32], is present in
approximately 25% of those 74-85 years and 50% of those
85 years or older, and places substantial financial burdens
on health care systems [33]. Hospital admissions is said
to account for the majority of health-care costs in devel-
oped countries. In Australia and the USA people aged
over 75 years spend 7-10 times as much time in hospital
as adults under 45 years [34],[35]. This is likely to
increase in coming years due to the ageing of the popula-
tion and hospital bed days are predicted to double by
2050 [34].
It has been hypothesised that improving nutritional
health through the administration of oral testosterone and
nutritional supplementation to community dwelling older
people over a period of 12 months may result in a reduc-
tion in hospitalisation and this will not only result in a
reduction in health care costs but also an improvement in
quality of life. Our research group have previously pub-
lished exciting pilot data from a small study that provides
further support for this hypothesis [36]. The Australian
National Health and Medical Research Council has now
funded this larger study to further investigate these
findings.
Therefore, the aims of this randomized control trial is to
determine the effects of treatment for one year with tes-
tosterone and high calorie nutritional supplementation
compared to placebo testosterone and low calorie nutri-
tional supplementation on the rate of hospital admissions
and other endpoints in under-nourished, community-
dwelling, older men and women.
Methods/Design
The study has been approved by the Human and
Research Ethics Committee of the Queen Elizabeth
Hospital, Adelaide, South Australia. The study has been
registered with the Australian Clinical Trial Registry:
ACTRN 12610000356066.
Recruitment and eligibility
Undernourished men and women, aged ≥ 65 years and
living independently in the community, will be recruited
in New South Wales, Victoria and South Australia (one
site in each state) by several methods:
a) Domiciliary geriatric assessment services at the
three campuses will approach new clients about
their willingness to consider participation in this
study and be approached by researchers.
b) Using similar approaches, investigator clinicians
and other geriatrician/gerontology colleagues will
refer consenting subjects from their rehabilitative,
ambulatory or outreach services for further contact
and review by the research officer. Any subjects who
have only recently been in hospital will be enrolled
into the study 3 months after the last hospitalization
and once health status is stabilized.
c) Television, radio or newspaper advertisements.
Information about the research study will be posted to
interested participants. Subjects will then be telephoned
by the research officer and will only proceed if the sub-
ject consents to further discussions occurring over the
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occur over the telephone to determine eligibility (i.e.
recent weight loss and estimated weight and height). If
subjects appear eligible and consent, the research officer
will visit the subjects at home or the subjects will come
to a clinic or a combination of these methods to deter-
mine subject eligibility for the study.
Primary and Secondary Outcomes
The primary endpoints in this study are number of days
in hospital, number of admissions and quality adjusted
life years (QALYs). Secondary endpoints are measures
of function, nutrition, strength, body composition,
inflammation and health service utilization.
Inclusion and Exclusion Criteria
In this study, the subject is said to be at-risk of under-
nutrition if they fulfill the following:
a) A Mini Nutritional Assessment (MNA) score
between 17 and 23.5 [37]; and
b) A body mass index (in kg/m
2) of <22 or a self-
reported weight loss of ≥7.5% in the 3 months
before enrolling in the study.
The following exclusion criteria are applied:
a) The inability to comply with the protocol;
b) Folstein’s Mini Mental State Examination score
≤23 [38];
c) Elevated hematocrit (>50%); history of prostate
cancer, prostate-specific antigen (PSA) concentra-
tions greater than the age-related normal range, or
an irregular prostate on examination;
d) A history of breast cancer in men and women;
e) Preexisting androgenic signs or symptoms of con-
cern (deep voice, hirsutism, acne, or androgenic hair
loss) in women;
f) Significant depressive symptoms using the Geria-
tric Depression Scale (short form) score ≥11 [39];
g) Cardiac failure corresponding to New York Heart
Association class III and above;
h) Myocardial infarction or stroke within the past 12
months, unstable angina, coronary artery procedure
(stent, angioplasty or coronary artery bypass grafting)
within the past 12 months, unstable arrhythmia (does
not include controlled atrial fibrillation);
i) Uncontrolled hypertension; systolic blood pressure
>170 mmHg and/or diastolic blood pressure >100
mmHg
j) Abnormal liver function tests (alanine aminotrans-
ferase, g-glutamyltransferase, bilirubin, or alkaline
phosphatase >2 times the upper limit of normal;
k) Estimated creatinine clearance < 30 ml/min (by the
equation of Baracskay and Jarjoura for ambulatory
elderly subjects [Cr clearance = 4.4/serum creatinine
(mmol/L) + (88-age)] AND/OR serum creatinine con-
centration > 0.2 mmol/l. [40]
l) Any disease that, in the opinion of the investiga-
tor, is likely to lead to death within 1 year;
m) Testosterone or other androgen therapy within 4
months of starting the study; and
n) Women on oestrogen or hormone replacement
therapy that have not been on a stable dose for the
last 3 months.
All subjects will give written informed consent prior to
commencement in the study. Subjects are able to with-
draw from the study at any time. Appropriate security and
de-identification measures will be used to ensure subject
confidentiality. An overview of the recruitment method,
randomization and following-up time points is shown in
Figure 1.
Randomization
Subjects will be randomized to one of two study groups
(n = ≈100/group) by a stratification system to ensure
that an equal number of men and women will be allo-
cated to each treatment. There will be stratification by
study site to allow for possible differences in subjects
recruited between sites, in blocks of 10 within each sex
at each site. To maintain blinding a master randomisa-
tion list will be developed and maintained by the
Research Pharmacy Department at the Royal Adelaide
Hospital in Adelaide. Separate lists will be developed for
each study site - the investigators will be blinded to
these treatment lists.
Interventions
All subjects will be advised that they have been assessed
as at-risk of being under-nutrition, and will be given
dietary advice about increasing their energy intake,
based on their responses to the MNA assessment as in
the previous study. In addition, the general practitioner
of all subjects will be notified in writing of this assess-
ment and of the subject’s participation in the study.
This will be designated ‘standard care’.
The two study groups will be:
a) Control: “standard care” + placebo testosterone +
placebo- low calorie supplement drink (< 200 kJ in
180 ml/day).
b) Combined treatment: “standard care” +o r a lt e s -
tosterone undecanoate (Andriol Testocaps 40 mg
orally once a day for women, 80 mg orally twice a
day for men) + high calorie nutritional supplement
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10 g fat, approx 40 g carbohydrate).
Testosterone undecanoate capsules are purchased and
a packaging company places these capsules in a larger
capsule. These larger capsules minus the testosterone act
as the placebo. Dissolution testing was conducted to
ensure that absorption of the active testosterone medica-
tion was not significantly altered. Subjects are advised to
take their testosterone/placebo tablets with meals (with
breakfast and evening dinner for men and with breakfast
for women). The high calorie nutritional supplement
used in this study is a 180 ml drink that is taken twice a
day. Two flavours are provided, Vanilla 1054 kJ/180 ml
and Chocolate 1208 kj/180 ml. Subjects on the active
treatment would receive approximately 2108-2416 kJ(360
ml)/day. The placebo consists of a low KJ (<200 KJ) drink
made up of artificial sweetener, flavour and xantham
gum to match the texture. The vanilla flavoured drink
delivers 70.97 kJ/180 mls and the chocolate flavoured
drink delivers 95.48 kJ/180 mls. Subjects on the placebo
treatment would receive approximately 142-191 kJ
(360 ml)/day.
At baseline the following assessments are conducted.
a. Nutritional assessment- completion of the Mini
Nutritional Assessment (MNA) [37] and determina-
tion of body mass index (weight/height
2)a n dt h e
presence of weight loss. The Simplified Nutrition
Appetite Questionnaire (SNAQ) [41] and a 24 hour
recall food diary will also be administered;
b. Documentation of medical history and medica-
tions including the completion of the Charlson co-
morbiditiy index [42];
c. Completion of the following validated question-
naires and assessments: Folstein’sM i n iM e n t a lS t a t e
Examination (MMSE) [38], Montreal Cognitive
Assessment (MOCA) (http://www.mocatest.org)[43],
15-item geriatric depression scale (15-GDS) [39],
Independent Activities of Daily Living scale (IADL)
[44], Barthel’s Index [45], the Cardiovascular Health
Study Frailty Phenotype Score [46], a retrospective
falls diary for the previous 12 months, a 24 hour food
recall diary, the 36-Item Short Form-36 Health Sur-
vey (SF-36) [47], for men International Prostate
Symptom Score [48], for women voice handicap
questionnaire [49], and a record of hospital admis-
sions over the previous year.
d. Completion of strength examination: 3 metre walk
time, dominant hand grip strength (Stoelting Hand
Grip Dynanometer; Stoelting Co, Wood Dale, IL),
timed chair rise time (time taken to perform 5 chair
rise and number performed in 30 seconds);
e. Digital rectal prostate examination (DRE) in men;
f. Dipstick urinalysis;
g. Body composition analysis by Bioelectrical Impe-
dance (BIA: Quantum II by RJL Systems [http://
www.rjlsystems.com/products]);
h. Biochemical analysis (fasting blood for glucose,
lipids, hematocrit [HCT], PSA [men only], electro-
lytes, liver function tests, high sensitivity C-Reactive
Protein (hsCRP), serum lipids, albumin, testosterone,
sex hormone binding globulin [SHBG], FSH, LH,
oestradiol); and
Participant Selection 
Assessed for eligibility
Consent
Baseline Assessment
Randomisation
Allocated control
Phone call and 
home visits
Allocated Intervention
Phone call and home 
visits
3 month Outcome
Assessment
6 month Outcome
Assessment
12 month Outcome
Assessment
End of study
Figure 1 Study design and assessment points.
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1, IL-6, TNF-a).
Further assessments at home or clinic occur at 3-
months, 6 months and 12 months as described in Table 1.
The protocol will be continued during, and after, any hos-
pitalization if this did not result in adverse effects or inter-
fere with any medical treatment. Subjects will be visited at
home at 3, 6, and 12 months for measurements of weight,
anthropometry, and grip strength and at 1, 2, 3, 4, 5, 6, 8,
10, and 12 months for assessment of dietary and medica-
tion compliance (tablet and empty packet count) and doc-
umentation of any change in medical conditions,
medications, living arrangements, or hospitalizations.
Details of hospital admissions are obtained from the sub-
ject and, with their written permission, from their general
practitioner. Where possible, hospital records, including
copies of discharge letters, are obtained. Compliance is
reinforced and assessed by phone calls every 2 weeks
b e t w e e nv i s i t s .T h eo c c u r r e n c eo fa n ya d v e r s ee v e n t si s
actively sought during these calls and visits.
Alterations to testosterone dosage
The study drug dose will be halved to one tablet twice a
day in men, and one tablet alternate days in women if
either of the following occur (confirmed by repeat test):
hematocrit > 54%; PSA more than 10% above the upper
end of the age-related normal range. The abnormal test
will be repeated in 6 weeks. If the value normalizes the
subject will continue the halved dose. If the result remains
elevated the study medication will be ceased permanently
(the abnormal value will be re-measured 6 weeks later and
then according to the study schedule) and the subject will
continue only with the nutritional supplement (or con-
trol). Men with persistently elevated PSA values will be
referred for further urological assessment. Women who
d e v e l o pa n d r o g e n i cs i d ee f f e c t sh a v et h eo p t i o no fs t o p -
ping the drug or halving the dose. If the dose is halved the
full dose will not be re-instituted later and the subject has
the option of stopping the study drug at any later time.
Data and Safety Monitoring
An independent data and safety monitoring committee,
consisting of a nutritional expert/scientist, geriatrician and
another specialist physician with experience on the drugs
and therapeutics committee who are independent of the
study investigations and unaware of the treatment assign-
ments will be established and co-ordinated from the
Queen Elizabeth Hospital. This committee will meet at
regular intervals to monitor for adverse events that war-
rant protocol modification or termination. For instance,
emergence of an unacceptable adverse effect profile with
Table 1 Proposed visits and measurements during the study
Screening Baseline 3 m 6 m 12 m
Screening Document X
Consent X
Baseline-demographics, illness, medications, Charlson co-morbidity index X
Chair rise test XX X
Weight XX X X
IPSS (men only) XX X X
MNA, SNAQ XX X
MMSE, MOCA, 15-GDS, IADL, Barthel Index X X X
Voice Handicap Index (women only) X X X X
Frailty, Grip Strength, physical activity (kcal/wk) X Grip only X X
SF-36 XX X
Body composition-resistance, reactance, fat mass, lean mass, TBW X X
Urinalysis and per rectal exam for men X
24 hour food diary (%fat, % CHO, %Protein, kcal) X X X
FBE (hematocrit) XX X X
PSA (men only) XX X X
Total Chol, Trig, HDL, LDL X X X
Biochem XX X
hsCRP XX X
Testosterone, SHBG XX X
LH, FSH, Oestradiol XX
Cytokines XX X
Flag any abnormal blood test results to CI X X X X
Send results to GP XX X X
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pilot study. Because of the size of the study and the nature
of the treatment and endpoints we have not included an
option for premature study termination due to high
efficacy.
Statistical and Cost-Effectiveness Analysis
All analyses will be performed according to the intention-
to-treat principle controlling for the effects of recruitment
site. The distribution of the number of hospitalizations in
each group will be compared using Fisher’se x a c tt e s t .
Times to admission will be analyzed using Cox propor-
tional hazards regression with account taken of within-
subject correlation for subjects with multiple admissions.
The numbers of days spent in hospital will be compared
using Mann-Whitney tests. Other data will be analysed
with a linear mixed model using residual maximum likeli-
hood (REML) and including all available time points.
A per-protocol analysis will also be undertaken. A cost-
effectiveness analysis will be undertaken from the perspec-
tive of the Australian public health care system and
include costs incurred by both the federal and state gov-
ernments in relation to health care. The primary outcome
measure for the cost-effectiveness analysis will be the qual-
ity adjusted life years (QALY) derived from SF_36 via the
SF-6D algorithm [50]. Patients will be asked for consent to
access their Pharmaceutical Benefits Scheme (PBS) and
Medicare Benefits Schedule (MBS) records. Consent will
also be requested to access patient information from the
Integrated South Australian Activity Collection (ISAAC),
which contains information on all hospital separations in
SA. Consent will also be requested to access patient infor-
mation from relevant State agencies which will contain
information on all hospital separations in each State, and
the related information on the costs associated with each
hospital separation. Data obtained will include patient
admission, and inpatient stay characteristics, as well as
providing ICD-10 categorised data on principle and addi-
tional diagnoses and procedures. These three data sources
will provide sufficient data to inform a detailed analysis of
the downstream cost consequences for the different treat-
ment groups.
Subjects will still be allowed to participate in the study
without providing consent to access these data. These
three data sources will provide sufficient data to inform a
detailed analysis of the downstream cost consequences
for the different treatment groups.
Mean costs and effectiveness between the intervention
and control groups will be compared and incremental
cost effectiveness ratios presented (ICERs) described. A
range of one-way and multi-way sensitivity analyses will
be undertaken to test the effect of uncertainties around
the true values of key resource use and effectiveness
parameters. Probabilistic sensitivity analysis will inform
confidence intervals around the ICER and cost-effective-
ness acceptability curves.
Power and Sample Size
The sample size is based on power calculations performed
on the results of the pilot study [36]. To have a power of
90% to detect a significant (at P = 0.05 [2-sided]) differ-
ence in the number of days of hospitalisation between the
treatment groups 28 subjects per group are required, and
to have a power of 90% to detect a significant (at P = 0.05
[2-sided]) difference in the number of subjects with non-
elective admissions 30 subjects per group are required.
The study is therefore substantially overpowered to
address the primary endpoint of hospitalisation. An exami-
nation of QALYs in the pilot study indicates that the no-
treatment group lost QALYs, while the combined treat-
ment group gained QALYS. 85 subjects per treatment arm
would be needed to have a power of 90% to show a signifi-
cant (P = 0.05 [2-sided]) QALY improvement of 0.05 with
the combined treatment. Assuming a net cost of providing
the treatment of AUS$2500 per year when used in the
community setting, a QALY difference of 0.05 would
result in an incremental cost per QALY gained of AUS
$50,000, the commonly implied threshold for cost effec-
tiveness (Medicines Australia Inc, A Prescription for the
Health of Australia 2002). Allowing for a margin of safety,
we therefore plan to study 200 subjects.
Discussion
There is limited high level evidence that any specific
interventions are effective strategies for community
dwelling older people identified as under-nourished who
are at-risk of morbidity and mortality [29,51]. Under-
nourished older people are likely to have sarcopenia and
this provides the basis for the use of an anabolic agent
such as oral testosterone. To date, the evidence for
functional benefits of testosterone treatment in older
people, other than increased strength, is limited. This
research group has previously reported that 12 month
combined treatment with oral testosterone and nutri-
tional supplement reduced the risk of hospitalization
compared to no treatment in a group of under-nour-
ished community dwelling older people. Previous studies
have reported that nutritional supplements have modest
benefits in older people, particularly in those who are
more undernourished, who are in hospitals or other
institutions, or who receive larger dose of supplements
for longer time periods [14,52]. This larger study will
provide researchers with further information allowing
determination of the effectiveness of this proposed inter-
vention strategy in this group of population (frail, older,
community dwelling and under-nourished).
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